Three Dividend Stocks Worth Investing In
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy ABBV?
Source: Fool
- AbbVie's Growth Potential: AbbVie successfully expanded its product portfolio and added Botox through a $63 billion acquisition of Allergan, and despite losing patent protection for its flagship drug Humira, the company still achieved over 12% revenue growth in Q1 2026, demonstrating strong growth potential.
- Verizon's Acquisition Advantage: With a dividend yield of 5.9%, Verizon attracts investors, and despite a 17% stock price increase this year, its forward P/E ratio is only 10; the acquisition of Frontier is expected to enhance its fiber access capabilities, further boosting future growth prospects.
- Canadian Natural Resources' Inflation Hedge: Canadian Natural Resources has seen its stock price rise 40% this year amid rising oil prices, and while its dividend yield stands at 3.8%, its forward P/E remains below 14, indicating strong profitability even in economic uncertainty.
- Sustained Dividend Growth: Canadian Natural Resources has raised its dividend for 26 consecutive years, averaging a compounded annual growth rate of about 20%, maintaining stable dividend payments even during periods of low oil prices, showcasing its appeal as a high-dividend stock.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ABBV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ABBV
Wall Street analysts forecast ABBV stock price to rise
18 Analyst Rating
12 Buy
6 Hold
0 Sell
Moderate Buy
Current: 205.030
Low
223.00
Averages
252.00
High
289.00
Current: 205.030
Low
223.00
Averages
252.00
High
289.00
About ABBV
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
AbbVie Surprises with Strong Q1 Earnings, Boosting Stock
- Significant Revenue Growth: AbbVie's Q1 revenue reached $15 billion, marking a 12.4% year-over-year increase and surpassing the expected $14.7 billion, showcasing the company's strong performance in immunology and boosting investor confidence.
- Strong Immunology Business: Sales of Skyrizi and Rinvoq exceeded management's expectations, with AbbVie now projecting combined revenues of over $31 billion for these drugs in 2023, four years ahead of the previous 2027 target, reflecting the company's competitive edge in the market.
- Potential Expansion Opportunities: Rinvoq is awaiting approval for alopecia areata treatment, while Skyrizi could gain a new indication for Crohn's disease, which will further drive sales growth and enhance AbbVie's market position.
- Long-Term Growth Outlook: AbbVie has raised its earnings per share guidance for 2026, and with its strong product lineup and robust dividend policy, the company remains an attractive investment despite a 10% decline in stock price year-to-date.
See More
AbbVie Presents New Data at Digestive Disease Week 2026
- Research Presentation: AbbVie showcased 18 abstracts at the 2026 Digestive Disease Week, highlighting long-term efficacy data for SKYRIZI and RINVOQ in Crohn's disease and ulcerative colitis, reinforcing its leadership in gastroenterology.
- Clinical Data Support: The studies indicate a low switch rate for SKYRIZI among Crohn's disease patients and a significant reduction in hospitalization rates after switching to RINVOQ, providing critical evidence for treatment decisions.
- Quality of Life Improvement: SKYRIZI has demonstrated improvements in health-related quality of life for Crohn's disease patients, with year-one results from the ASPIRE-CD study showing significant symptom relief, indicating its clinical application potential.
- FDA Application Progress: On April 27, 2026, AbbVie submitted an application to the FDA seeking approval for SKYRIZI's subcutaneous induction treatment in adult patients with Crohn's disease, which, if approved, will further expand its market share.
See More
Dividend Stocks Comparison: Johnson & Johnson vs. AbbVie
- Diversification Advantage: Johnson & Johnson's diversified operations in pharmaceuticals and medical devices allow it to maintain stability in a competitive market, with revenue growth despite losing Stelara's patent, and it is projected to reach $100 billion in revenue by 2026, becoming only the second biopharma to achieve this milestone in history.
- Core Growth Drivers for AbbVie: AbbVie's leadership in immunology led to $15 billion in revenue in Q1, a 12.4% year-over-year increase, with Skyrizi and Rinvoq contributing $6.6 billion, showcasing strong market performance, though it faces competitive risks.
- Dividend Growth History: Johnson & Johnson has raised its dividends for 64 consecutive years compared to AbbVie's 54 years, indicating stronger financial stability and long-term investment appeal, particularly in the current market environment, with its AAA credit rating further enhancing its attractiveness as a low-risk investment.
- Market Risks and Opportunities: While Johnson & Johnson faces litigation risks related to its talc products, its diversified portfolio enables it to navigate challenges like drug pricing negotiations, whereas AbbVie shows potential in new product launches, especially with its weight-loss treatment performing well in clinical trials.
See More
Analysis of IVV ETF's 52-Week Price Fluctuations
- Price Range Analysis: The IVV ETF's 52-week low is $558.69 per share, with a high of $734.02, and the latest trade at $733.89 indicates stability near its peak, potentially attracting investor interest.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides valuable insights for investors, aiding in market trend assessment and potential buying opportunities.
- Unit Trading Mechanism: ETFs trade similarly to stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting the ETF's liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding highlights notable inflows (new units created) or outflows (old units destroyed), directly affecting the ETF's underlying holdings and its market performance.
See More
High Dividend Stocks Investors Should Focus On
- AbbVie Dividend Stability: AbbVie declared a quarterly cash dividend of $1.73 per share, and despite losing patent protection for Humira, the company has successfully achieved growth through strategic acquisitions and R&D investments, indicating a strong potential for continued dividends in the future.
- Significant Dividend Growth: Since its spin-off in 2013, AbbVie has increased its dividend by over 332%, with a 33% growth in the past five years, and a current dividend yield of 3.27%, which, although below historical averages, still reflects the company's robust profitability.
- Realty Income's Monthly Dividends: Realty Income, known as
See More
AbbVie and Realty Income's Stable Dividend Prospects
- AbbVie Dividend Growth: AbbVie's board declared a quarterly cash dividend of $1.73 per share, payable on May 15, 2026, demonstrating the company's ability to increase dividends for 54 consecutive years, even amidst patent expiration challenges, while maintaining robust business growth.
- Dividend Yield Performance: AbbVie's forward dividend yield stands above 3.3%, although below its historical average, yet its solid stock price appreciation and 33% dividend growth over the past five years indicate effective inflation management.
- Realty Income Stability: Realty Income has paid dividends for 670 consecutive quarters since going public in 1994, with a forward dividend yield exceeding 5%, showcasing its ability to generate steady cash flow and maintain a high occupancy rate of 98.9% even during economic fluctuations.
- Market Growth Potential: Realty Income's total addressable market is estimated at $13 trillion, with $8.5 trillion in Europe, indicating significant growth potential in a highly fragmented market, which suggests the company can continue to provide substantial monthly dividends to investors.
See More
AbbVie Surprises with Strong Q1 Earnings, Boosting Stock
- Significant Revenue Growth: AbbVie's Q1 revenue reached $15 billion, marking a 12.4% year-over-year increase and surpassing the expected $14.7 billion, showcasing the company's strong performance in immunology and boosting investor confidence.
- Strong Immunology Business: Sales of Skyrizi and Rinvoq exceeded management's expectations, with AbbVie now projecting combined revenues of over $31 billion for these drugs in 2023, four years ahead of the previous 2027 target, reflecting the company's competitive edge in the market.
- Potential Expansion Opportunities: Rinvoq is awaiting approval for alopecia areata treatment, while Skyrizi could gain a new indication for Crohn's disease, which will further drive sales growth and enhance AbbVie's market position.
- Long-Term Growth Outlook: AbbVie has raised its earnings per share guidance for 2026, and with its strong product lineup and robust dividend policy, the company remains an attractive investment despite a 10% decline in stock price year-to-date.
See More
AbbVie Presents New Data at Digestive Disease Week 2026
- Research Presentation: AbbVie showcased 18 abstracts at the 2026 Digestive Disease Week, highlighting long-term efficacy data for SKYRIZI and RINVOQ in Crohn's disease and ulcerative colitis, reinforcing its leadership in gastroenterology.
- Clinical Data Support: The studies indicate a low switch rate for SKYRIZI among Crohn's disease patients and a significant reduction in hospitalization rates after switching to RINVOQ, providing critical evidence for treatment decisions.
- Quality of Life Improvement: SKYRIZI has demonstrated improvements in health-related quality of life for Crohn's disease patients, with year-one results from the ASPIRE-CD study showing significant symptom relief, indicating its clinical application potential.
- FDA Application Progress: On April 27, 2026, AbbVie submitted an application to the FDA seeking approval for SKYRIZI's subcutaneous induction treatment in adult patients with Crohn's disease, which, if approved, will further expand its market share.
See More
Dividend Stocks Comparison: Johnson & Johnson vs. AbbVie
- Diversification Advantage: Johnson & Johnson's diversified operations in pharmaceuticals and medical devices allow it to maintain stability in a competitive market, with revenue growth despite losing Stelara's patent, and it is projected to reach $100 billion in revenue by 2026, becoming only the second biopharma to achieve this milestone in history.
- Core Growth Drivers for AbbVie: AbbVie's leadership in immunology led to $15 billion in revenue in Q1, a 12.4% year-over-year increase, with Skyrizi and Rinvoq contributing $6.6 billion, showcasing strong market performance, though it faces competitive risks.
- Dividend Growth History: Johnson & Johnson has raised its dividends for 64 consecutive years compared to AbbVie's 54 years, indicating stronger financial stability and long-term investment appeal, particularly in the current market environment, with its AAA credit rating further enhancing its attractiveness as a low-risk investment.
- Market Risks and Opportunities: While Johnson & Johnson faces litigation risks related to its talc products, its diversified portfolio enables it to navigate challenges like drug pricing negotiations, whereas AbbVie shows potential in new product launches, especially with its weight-loss treatment performing well in clinical trials.
See More
Analysis of IVV ETF's 52-Week Price Fluctuations
- Price Range Analysis: The IVV ETF's 52-week low is $558.69 per share, with a high of $734.02, and the latest trade at $733.89 indicates stability near its peak, potentially attracting investor interest.
- Technical Analysis Tool: Comparing the latest share price to the 200-day moving average provides valuable insights for investors, aiding in market trend assessment and potential buying opportunities.
- Unit Trading Mechanism: ETFs trade similarly to stocks, where investors buy and sell 'units' that can be created or destroyed based on demand, impacting the ETF's liquidity and market performance.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding highlights notable inflows (new units created) or outflows (old units destroyed), directly affecting the ETF's underlying holdings and its market performance.
See More
High Dividend Stocks Investors Should Focus On
- AbbVie Dividend Stability: AbbVie declared a quarterly cash dividend of $1.73 per share, and despite losing patent protection for Humira, the company has successfully achieved growth through strategic acquisitions and R&D investments, indicating a strong potential for continued dividends in the future.
- Significant Dividend Growth: Since its spin-off in 2013, AbbVie has increased its dividend by over 332%, with a 33% growth in the past five years, and a current dividend yield of 3.27%, which, although below historical averages, still reflects the company's robust profitability.
- Realty Income's Monthly Dividends: Realty Income, known as
See More
AbbVie and Realty Income's Stable Dividend Prospects
- AbbVie Dividend Growth: AbbVie's board declared a quarterly cash dividend of $1.73 per share, payable on May 15, 2026, demonstrating the company's ability to increase dividends for 54 consecutive years, even amidst patent expiration challenges, while maintaining robust business growth.
- Dividend Yield Performance: AbbVie's forward dividend yield stands above 3.3%, although below its historical average, yet its solid stock price appreciation and 33% dividend growth over the past five years indicate effective inflation management.
- Realty Income Stability: Realty Income has paid dividends for 670 consecutive quarters since going public in 1994, with a forward dividend yield exceeding 5%, showcasing its ability to generate steady cash flow and maintain a high occupancy rate of 98.9% even during economic fluctuations.
- Market Growth Potential: Realty Income's total addressable market is estimated at $13 trillion, with $8.5 trillion in Europe, indicating significant growth potential in a highly fragmented market, which suggests the company can continue to provide substantial monthly dividends to investors.
See More
